Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr

The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25

Laurus Labs invests in Laurus Bio

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19

Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment

It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT

ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.

Laurus Labs PAT at Rs 201.90 cr. in Q2FY21

Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021